In a report published Thursday, ROTH Capital analysts initiated coverage on PlasmaTech Biopharmaceuticals, Inc. (PTBI) with a ‘Buy‘ rating and $16 price target. On valuation measures, PlasmaTech Biopharmaceuticals Inc. shares have a t-12 price/sales ratio of 175.97. EPS is ($4.42). Currently there is only one analyst rating PTBI a ‘Buy’. No analyst rates it a […] View the full post at: Notable Upgrades: PlasmaTech (PTBI), Netflix (NFLX), Citrix Systems (CTXS), AVG Technologies (AVG) Related posts: Netflix (NFLX) Boosts Prize Economics Align Technologies Takes One in the Teeth Moody’s Upgrades (JAS, F, COT)